| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.069 | 0.1 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.1 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.045 | 0.1 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.072 | 0.1 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | -0.25 | 0.1 |